MIAMI, July 1 /PRNewswire/ -- FUISZ today announced two medical technology advances.
First, FUISZ announcedthat it has received a notice of issuance from the United States Patent and Trademark Office for patent claims that cover a direct connection between prescribing physicians and blood analysis devices. The invention allows for the health care provider
FUISZ also announced that it has filed a new patent in the field of solid oral Bioactive dosage forms. This novel system works to enhance or retard drug absorption. It is particularly well suited to buccal, sublinqual and other forms of mucosal delivery including nano particles. Joseph Fuisz commented, "This innovation can be readily adapted for use with existing products to improve control of drug absorption. It will be particularly well received in the opiate market where controlling relative absorption of opiates and agonists is so critical. This technology draws upon our deep knowledge of quick dissolve dosage forms and applies that knowledge in a broad manner to all solid dosage forms."
FUISZ is a family owned company. Fuisz principals Richard Fuisz, M.D. and Joseph Fuisz, Esq. are named inventors on or owners of hundreds of patents and patent applications. These patents span several fields: drug delivery, quick dissolve dosage forms including quick dissolve tablets, thin films, slow dissolve sheets, conventional oral dosage units, opiate abuse resistance, women's health, electronic mail, e-commerce, and tobacco. The company is based in Miami, Florida. www.fuisz.com.
Subscribe to our Free Newsletters!
Cholestatic jaundice occurs when the flow of bile (chole) between the liver and small intestine is ...
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...View All